

## **CURRICULUM VITAE**

**SUSAN E. ANDRADE**

BUSINESS: Meyers Primary Care Institute  
630 Plantation Street  
Worcester, MA 01605  
(508)791-7392

### **EDUCATION**

1988 Bachelor of Science, Pharmacy, University of Rhode Island  
1994 Doctor of Science, Epidemiology, Harvard School of Public Health  
Thesis: *Epidemiology of Antihyperlipidemic Drug Discontinuations*

### **ACADEMIC APPOINTMENTS**

1994-1996 Assistant Professor of Pharmacoepidemiology, non-tenure track position, Department of Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island  
1996-2001 Assistant Professor of Pharmacoepidemiology, tenure track position, Department of Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island  
2001 Associate Professor of Pharmacoepidemiology (tenured), Department of Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island  
2001-2007 Assistant Professor, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts  
2001-2012 Research Associate Professor, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts

### **OTHER PROFESSIONAL EXPERIENCE**

1988-1995 Registered Pharmacist, CVS Pharmacy, Woonsocket, Rhode Island  
1989-1990 Research Assistant, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts  
1994-1996 Program Analyst, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts  
1996- Senior Research Associate, Meyers Primary Care Institute, Worcester, Massachusetts

### ***Internships***

1985-1988 Pharmacy Intern, CVS Pharmacy, Woonsocket, Rhode Island  
1987 Research Assistant, Departments of Biophysical Chemistry and Medicinal Organic Chemistry, Brown University and University of Rhode Island, Providence, Rhode Island  
1988 Pharmacy Intern, Roger Williams Hospital and Women and Infants Hospital,

1992 Providence, Rhode Island  
Research Intern, Corporate Drug Safety, Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany

### **CONSULTANCIES**

1993-1995 Research consultant in pharmacoepidemiology, Epidemiology Resources Inc., Newton Lower Falls, Massachusetts  
1996- Consulting to health care plan and pharmaceutical manufacturing and medical diagnostics companies in the area of pharmacoepidemiology  
1996-2001 Research consultant in pharmacoepidemiology, Meyers Primary Care Institute, Worcester, Massachusetts

### **TEACHING EXPERIENCE**

#### ***Course Instructor***

1994-2000 Public Health, University of Rhode Island  
1996 Pharmacoeconomic Analysis, University of Rhode Island  
1997-2000 Public Health Practicum in Emerging Infectious Diseases, University of Rhode Island  
1998-2000 Pharmacoepidemiology, University of Rhode Island

#### ***Teaching Assistant***

1991 Principles of Epidemiology, Harvard School of Public Health  
1993 Pharmacoepidemiology, Harvard School of Public Health  
1991-1994 Teaching Fellow, Department of Epidemiology, Harvard School of Public Health

### **HONORS AND AWARDS**

1998 Thomas M. Ryan/CVS Chair in Community Pharmacy  
2004 ISPE – Pharmacoepidemiology and Drug Safety Distinguished Article Award

### **PROFESSIONAL LICENSES**

1988 Registered pharmacist (Rhode Island, Massachusetts)

### **MEMBERSHIPS IN PROFESSIONAL SOCIETIES**

1991- International Society for Pharmacoepidemiology  
1991-2000 Society for Epidemiologic Research  
1988- American Pharmaceutical Association  
1996-2000 American Association of Colleges of Pharmacy

1999-2001 Rhode Island Pharmacists' Association

## **PRESENTATIONS**

### ***Invited Presentations***

- 1994 Seminar Speaker, "Desktop Manipulation of Large Health Care Databases," Pharmacoepidemiology Seminar Series, Harvard School of Public Health, Boston, Massachusetts
- 1995 Speaker, "Statistical Issues in Clinical Research," Basic Science Lecture Series, St. Vincent Hospital, Worcester, Massachusetts
- 1995 Continuing Pharmacy Education Course Speaker, "Treatment of Hypercholesterolemia: The Success of Antihyperlipidemic Drug Therapy in Primary Care Settings," Issues in Patient Management of Hypercholesterolemia Pharmacy Program, Needham, Massachusetts
- 1995 Continuing Pharmacy Education Course Speaker, "Pharmacoepidemiology and Pharmacoeconomics: The Example of Cholesterol-Lowering Drug Therapy," University of Rhode Island
- 1996 Symposium Speaker, "Comparative Safety of Analgesics," Novalgin Symposium, Rimbo, Sweden
- 1997 Symposium Speaker, "Safety Profile of Dipyrone," Novalgin Assessment Meeting, New York, New York
- 2005 Seminar Speaker, "Prescription Drug Use During Pregnancy," Pharmacoepidemiology Seminar Series, Harvard School of Public Health, Boston, Massachusetts

### ***Presentations, Scientific Conferences***

- 1991 "Determinants of Adverse Effects and Therapeutic Failure With Antihyperlipidemic Drug Therapy," 7th International Conference on Pharmacoepidemiology, Basel, Switzerland
- 1992 "Change in Drug Use: Switch or Supplementation to Existing Therapy," 8th International Conference on Pharmacoepidemiology, Minneapolis, Minnesota
- 1994 "Effects of Gender and Age on the Discontinuation Rate of Antihyperlipidemic Drug Therapy," 10th International Conference on Pharmacoepidemiology, Stockholm, Sweden
- 1994 "Antihyperlipidemic Drug Discontinuations: Do Rates Reported in Clinical Trials Predict Rates in Primary Care Settings," 10th International Conference on Pharmacoepidemiology, Stockholm, Sweden

- 1994 "Discontinuation of Drug Therapy: Assessment By Means of Automated Databases," 10th International Conference on Pharmacoepidemiology, Stockholm, Sweden
- 1997 "Rates of Hospitalization During Antihyperlipidemic Drug Use and After Discontinuation of Therapy," HMO Research Network Conference, Cambridge, Massachusetts
- 1997 "Lipid Studies: Compliance and the Real World," Association for Pharmacoeconomics and Outcomes Research Conference on Pharmacoeconomics and Outcomes Research Issues of Lipid Therapy, Orlando, Florida
- 1997 "Hospitalization Rates During Antihyperlipidemic Drug Use and After Discontinuation of Therapy," Drug Information Association Conference on Persistence/Compliance Among Patients on Drug Therapy, Baltimore, Maryland
- 1999 "Evaluation of a Comprehensive Formulary Switch in the Managed Care Setting: the Case of Hormone Replacement Therapy," 15th International Conference on Pharmacoepidemiology, Boston, Massachusetts
- 2000 "Hepatic Transaminase Testing Frequency and Patterns in Patients on HMG-CoA Reductase Inhibitors," 16th International Conference on Pharmacoepidemiology, Barcelona, Spain
- 2001 "Drug Benefit Plans Under Managed Care: To What Extent Do Elderly Subscribers Selecting Less Drug Coverage Put Themselves at Increased Financial Responsibility?" 17th International Conference on Pharmacoepidemiology, Toronto, Canada
- 2002 "Utilization of Controller Medications Among Adults Receiving Asthma Drugs" HMO Research Network 8th Annual Conference, Long Beach, California
- 2002 "Temporal Trends in Asthma Drug Utilization Among Adults" HMO Research Network 8th Annual Conference, Long Beach, California
- 2003 "Prescription Drug Use Before and During Pregnancy" HMO Research Network 9th Annual Conference, Denver, Colorado
- 2004 "Recommendations For Safer Drug Use in Pregnancy" Agency for Healthcare Research and Quality Expert Meeting on Improving the Use and Safety of Medications in Women Through Gender and Race Analysis, Rockville, Maryland
- 2005 "Antidiabetic Drug Treatment Patterns and Glycemic Control in a U.S. Managed Care Population" 21st International Conference on Pharmacoepidemiology, Nashville, Tennessee
- 2007 "Use of Cardiovascular Medications During Pregnancy" HMO Research Network 13th Annual Conference, Portland, Oregon

- 2009 "Medication Exposure in Pregnancy Risk Evaluation Program" HMO Research Network 15th Annual Conference, Danville, Pennsylvania
- 2010 Seminar Speaker, "Pharmacoepidemiologic Research Program: Examples of Current Adverse Events Research," 2010 Spring Practice and Research Forum, American College of Clinical Pharmacy, Charlotte, North Carolina
- 2011 "Developing Validated Algorithms To Ascertain Medical Procedures Used During Pregnancy And Related Clinical Conditions " HMO Research Network 17th Annual Conference, Boston, MA

## **BIBLIOGRAPHY**

### ***Journal Articles***

- Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, Platt R. Discontinuation of antihyperlipidemic drugs: Do rates reported in clinical trials reflect rates in primary care settings? *N Engl J Med* 1995;332:1125-1131.
- Andrade SE, Platt R, Gottlieb LK, Saperia GM, Walker AM. Discontinuation of antihyperlipidemic drug therapy: assessment by means of automated databases. *Pharmacoepidemiol Drug Saf* 1996;5:113-120.
- Andrade SE, Saperia GM, Gottlieb LK, Walker AM, Platt R. Effects of gender, age, and previous discontinuation of therapy on the discontinuation rate of antihyperlipidemic drug therapy. *Cardiovascular Risk Factors* 1997;7:167-172.
- Andrade SE. Lipid therapy and compliance. *Drug Benefit Trends* 1998;10:39-43,52.
- Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of nonnarcotic analgesics. *J Clin Epi* 1998;51:1357-1365.
- Andrade SE and Willey C. H2 receptor antagonist use among Medicaid patients enrolled in managed care health plans. *Clinical Research and Regulatory Affairs* 1998;15:131-144.
- Andrade SE. Lipid pharmaco-economic studies: compliance in the real world. *Value in Health* 1998;1:171-173.
- Donahue JG, Andrade SE, Cain EM, Defor TA, Goodman MJ, Gurwitz J, Platt R. Lamotrigine and severe skin eruptions. *Pharmacoepidemiol Drug Saf* 1998;7:415-7.
- Andrade SE, Gurwitz JH, Fish LS. The effect of an rx-to-otc switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. *Medical Care* 1999;37:424-430.
- Andrade SE, Saperia GM, Berger ML, Platt R. Effectiveness of antihyperlipidemic drug management in clinical practice. *Clin Ther* 1999;21:1973-1987.

Chan KA, Andrade SE, Boles M, Buist DSM, Chase G, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. HMG-CoA reductase inhibitors and reduced risk of fracture among older women. *Lancet* 2000;355:2185-2188.

Harrold LR, Yood R, Andrade S, Reed J, Cernieux J, Straus W, Weeks M, Lewis B, Gurwitz JH. Evaluating the validity of osteoarthritis diagnoses in an administrative database. *Arthritis Rheum* 2000;43:1881-1885.

Andrade SE, Gurwitz JH, Cernieux J, Fish LS. Evaluation of a formulary switch from conjugated to esterified estrogens in a managed care setting. *Medical Care* 2000;38:970-975.

Harrold LR, Gurwitz JH, Field TS, Andrade SE, Fish LS, Jarry PD, Yood R. The diffusion of a novel therapy into general medical practice: the case of sildenafil. *Arch Intern Med* 2000;160:3401-3405.

Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, Chan KA, Platt R, Schech SD, Ray WA. Contraindicated use of cisapride: the impact of food and drug administration regulatory action. *JAMA* 2000;284:3036-3039.

Ward A, Willey C, Andrade S. Medications provided to asthmatic children: a historical cohort study comparing clinical practice with NIH recommendations. *Pharmacoepidemiol Drug Saf* 2000;9:511-520.

Ward A, Willey C, Andrade S. Patient education provided to asthmatic children: a historical cohort study of the implementation of NIH recommendations. *J Asthma* 2001;38(2):141-147.

Platt R, Davis R, Finkelstein J, Go AS, Gurwitz JH, Roblin D, Soumerai S, Ross-Degnan D, Andrade S, Goodman MJ, Martinson B, Raebel MA, Smith D, Ulcickas-Yood M, Chan A. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research in Therapeutics (CERT). *Pharmacoepidemiol Drug Saf* 2001;10:373-377.

Andrade SE, Gurwitz JH. Drug benefit plans under managed care: to what extent do older subscribers selecting less drug coverage put themselves at increased financial risk? *J Am Geriatr Soc* 2002;50:178-181.

Andrade SE, Gurwitz JH, Chan KA, Donahue JG, Beck A, Boles M, Buist DSM, Goodman M, LaCroix AZ, Levin TR, Platt R. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. *J Clin Epi* 2002;55:310-313.

Donahue JG, Chan KA, Andrade SE, Beck A, Boles M, Buist DS, Carey VJ, Chandler JM, Chase GA, Ettinger B, Fishman P, Goodman M, Guess HA, Gurwitz JH, LaCroix AZ, Levin TR, Platt R. Gastric and duodenal safety of alendronate. *Arch Intern Med* 2002;162:936-942.

Putnam KG, Buist DS, Fishman P, Andrade SE, Boles M, Chase GA, Goodman MJ, Gurwitz JH, Platt R, Raebel MA, Chan KA. Chronic disease score as a predictor of subsequent hospitalization: a multi-HMO study. *Epidemiology* 2002;13:340-346.

Harrold LR, Yood RA, Straus W, Andrade SE, Reed JI, Cernieux J, Lewis B, Gurwitz JH. The challenges of estimating health service utilization for osteoarthritis patients on a population level. *J Rheumatol* 2002;29:1931-1936.

Gurwitz JH, Andrade SE. Risk management in therapeutics: when the patient becomes the last line of defense. *Pharmacoepidemiol Drug Saf* 2002;11:637-639.

Andrade SE, Donahue JG, Chan KA, Watson DJ, Platt R. Liver function testing in patients on HMG-CoA reductase inhibitors. *Pharmacoepidemiol Drug Saf* 2003;12:307-313.

Andrade SE, Majumdar SR, Chan KA, Buist DSM, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. *Arch Intern Med* 2003;163:2052-2057.

Andrade SE, Gurwitz JH, Field TS, Kelleher M, Majumdar SR, Reed G, Black R. Hypertension management: the care gap between clinical guidelines and clinical practice. *Am J Manag Care* 2004;10:481-486.

Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Ulcickas Yood M, Morse AN, Platt R. Prescription drug use in pregnancy. *Am J Obstet Gynecol* 2004;191:398-407.

Kogut SJ, Andrade SE, Willey CW, Larrat EP. Nonadherence as a predictor of antidiabetic therapy intensification (augmentation). *Pharmacoepidemiol Drug Saf* 2004;13:591-598.

Abughosh SM, Kogut SJ, Andrade SE, Larrat EP, Gurwitz JH. Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. *J Manag Care Pharm* 2004;10:404-411.

Harrold LR, Andrade SE, Eisner M, Buist AS, Go A, Vollmer WM, Chan KA, Frazier EA, Weller PF, Wechsler ME, Davis KJ, Platt R. Identification of patients with Churg-Strauss syndrome (CSS) using automated data. *Pharmacoepidemiol Drug Saf* 2004;13:661-667.

Buist DSM, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L. Hormone therapy prescribing patterns in the United States. *Obstet Gynecol* 2004;104:1042-1050.

Stille CJ, Andrade SE, Huang S, Nordin J, Raebel MA, Go AS, Chan KA, Finkelstein JA. Increased use of second-generation macrolide antibiotics for children in nine US health plans. *Pediatrics* 2004; 114:1206-1211.

Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, Le Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *JAMA* 2004;292:2585-2590.

Simon SR, Chan KA, Soumerai SB, Wagner AK, Andrade SE, Feldstein AC, Lafata J, Davis RL, Gurwitz JH. Potentially inappropriate medication use among elderly persons in U.S. HMOs, 2000-2001. *J Am Geriatr Soc* 2005;53:227-232.

Andrade SE, Graham DJ, Staffa JA, Schech SD, Shatin D, La Grenade L, Goodman MJ, Platt R, Gurwitz JH, Chan KA. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. *J Clin Epi* 2005;58:171-174.

Newton KM, Buist DS, Miglioretti DL, Beverly K, Hartsfield CL, Arnold KA, Andrade SE, Wei F, Connelly MT, Kessler L. The impact of comorbidities on hormone use after the 2002 release of the Women's Health Initiative. *J Gen Intern Med* 2005;20:350-356.

Harrold LR, Andrade SE, Go AS, Buist AS, Eisner M, Vollmer WM, Chan KA, Frazier EA, Weller PF, Wechsler ME, Yood RA, Davis KJ, Platt R. Incidence of Churg-Strauss syndrome (CSS) in asthma drug users: a population-based perspective. *J Rheumatol* 2005;32:1076-1080.

Roblin DW, Platt R, Goodman MJ, Hsu JT, Nelson WW, Smith DH, Andrade SE, Soumerai SB. Effect of increased cost-sharing on oral hypoglycemic use in five MCOs: how much is too much? *Medical Care* 2005;43:951-959.

Hartsfield CL, Connelly MT, Newton KM, Andrade SE, Wei F, Buist DS. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response. *Journal of the National Cancer Institute* 2005;2005:113-115.

Wei F, Miglioretti DL, Connelly MT, Andrade SE, Newton KM, Hartsfield CL, Chan KA, Buist DS. Changes in hormone use after the Women's Health Initiative estrogen and progestin trial by race, education, and income. *Journal of the National Cancer Institute* 2005;2005:106-112.

Raebel MA, Ellis JL, Andrade SE. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. *Pharmacoepidemiol Drug Saf* 2005;14:829-836.

Mazor KM, Andrade SE, Auger J, Fish L, Gurwitz JH. Communicating safety information to physicians: an examination of dear doctor letters. *Pharmacoepidemiol Drug Saf* 2005;14:869-875.

McPhillips HA, Stille CJ, Smith D, Hecht J, Pearson J, Stull J, DeBellis K, Andrade S, Miller M, Kaushal R, Gurwitz J, Davis RL. Medication Dosing Errors in Outpatient Pediatrics. *J Pediatrics* 2005;147:761-767.

Simon SR, Andrade SE, Ellis JL, Nelson WW, Gurwitz JH, Lafata JE, Davis RL, Feldstein A, Raebel MA. Baseline laboratory monitoring of cardiovascular medications among elderly health maintenance organization enrollees. *J Am Geriatr Soc* 2005;53:2165-2169.

Raebel MA, Lyons EE, Andrade SE, Chan KA, Chester EA, Davis RL, Ellis JL, Feldstein A, Gunter MJ, Lafata JE, Long CL, Magid DJ, Selby JV, Simon SS, Platt R. Laboratory monitoring of high risk drugs at initiation of therapy in ambulatory care. *J Gen Intern Med* 2005;20:1120-1126.

Raebel MA, Carroll NM, Andrade SE, Chester EA, Lafata JE, Feldstein A, Gunter MJ, Nelson WW, Simon SR, Chan KA, Davis RL, Platt R. Monitoring of drugs with a narrow therapeutic range in ambulatory care. *Am J Manag Care* 2006;12:268-74.



Wagner AK, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Lafata JE, Davis RL, Gurwitz JH, Soumerai SB, Platt R. FDA drug prescribing warnings: Is the black box half empty or half full? *Pharmacoepidemiol Drug Saf* 2006;15:369-386.

Wiley CJ, Andrade SE, Cohen J, Fuller JC, Gurwitz JH. Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. *Am J Manag Care* 2006;12:435-440.

Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Roblin D, Smith DH, Ulcickas Yood M, Platt R, Gurwitz JH. Use of prescription medications with a potential for fetal harm among pregnant women. *Pharmacoepidemiol Drug Saf* 2006;15:546-554.

Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. *Pharmacoepidemiol Drug Saf* 2006;15:565-574.

Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, Chan KA, Roblin D, Raebel MA, Von Worley A, Platt R, Saag KG. Sex differences in gout epidemiology, evaluation and treatment. *Ann Rheum Dis* 2006;65:1368-72.

Raebel MA, Carroll NM, Simon SR, Andrade SE, Feldstein AC, Lafata JE, Nelson WW, Chan KA, Gunter MJ, Tolsma D, Platt R. Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. *J Manag Care Pharm* 2006;12:656-664.

Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, Blough D, Stergachis A, Shatin D, Chan KA, Platt R. Risk factors for statin-associated rhabdomyolysis. *Pharmacoepidemiol Drug Saf* 2007;16:352-358.

Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, Lafata JE, Roblin D, Davis RL, Gunter MJ, Platt R. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. *Pharmacoepidemiol Drug Saf* 2007;16:55-64.

Harrold LR, Saag KG, Yood RA, Mikuls TR, Andrade SE, Fouayzi H, Davis J, Chan KA, Raebel MA, Von Worley A, Platt R. Validity of gout diagnoses in administrative data. *Arthritis Rheum* 2007;57:103-108.

Raebel MA, McClure DL, Chan KA, Simon SR, Feldstein AC, Lafata JE, Andrade SE, Gunter MJ, Nelson WW, Roblin D, Platt R. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? *Ann Pharmacother* 2007;41:193-200.

Herrinton LJ, Liu L, Lafata JE, Allison JE, Andrade SE, Korner EJ, Chan KA, Platt R, Hiatt D, O'Connor S. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. *Inflamm Bowel Dis* 2007;13:451-461.

Harrold LR, Patterson MK, Andrade SE, Dube T, Go AS, Buist AS, Chan KA, Weller PF, Wechsler ME, Yood RA, Davis KJ, Platt R, Walker AM. Asthma drug use and the development of Churg-Strauss syndrome (CSS). *Pharmacoepidemiol Drug Saf* 2007;16:620-626.

Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Platt R. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. *Pharmacoepidemiol Drug Saf* 2007;16:1086-1094.

Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. *Pharmacoepidemiol Drug Saf* 2007;16:1275-1284.

Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. *Bone* 2007;41:882-887.

Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Dal Pan GJ, Scott PE, Platt R. Outpatient use of cardiovascular drugs during pregnancy. *Pharmacoepidemiol Drug Saf* 2008;17:240-247.

Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence across seven medical conditions. *Pharmacotherapy* 2008;28:437-443.

Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R. Use of antidepressant medications during pregnancy: a multi-site study. *Am J Obstet Gynecol* 2008;198:194.e1-5.

Goff SL, Feld A, Andrade SE, Mahoney L, Beaton SJ, Boudreau DM, Davis RL, Goodman M, Hartsfield CL, Platt R, Roblin D, Smith D, Yood MU, Dodd K, Gurwitz JH. Administrative data used to identify patients with irritable bowel syndrome. *J Clin Epidemiol* 2008;61:617-621.

Newton KM, Buist DSM, Yu O, Hartsfield CL, Andrade SE, Wei F, Connelly MT, Chan KA. Hormone therapy initiation after the Women's Health Initiative. *Menopause* 2008;15:487-493.

Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. *J Gen Intern Med* 2008;23:1815-1821.

Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. *Pharmacoepidemiol Drug Saf* 2009;18:246-252.

Brown JS, Kulldorff M, Reynolds R, Petronis KR, Chan KA, Davis RL, Graham D, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R. Early adverse drug event signal detection within population-based health networks using sequential methods: Key methodologic considerations. *Pharmacoepidemiol Drug Saf* 2009;226-234.

Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and the use of generic drug therapies. *Am J Manag Care* 2009;15:450-456.

Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. *Semin Arthritis Rheum* 2009;38:396-402.

Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS. Adherence with urate-lowering therapies for the treatment of gout. *Arthritis Res Ther* 2009;11:R46.

Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. *Am J Med* 2010;123:275-280.

Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS. Dynamics of chronic gout treatment: medication gaps and return to therapy. *Am J Med* 2010;123:54-59.

Yood RA, Andrade SE, Mazor KM, Fouyazi H, Chan W, Kahler K. Bone density consequences of initiation and compliance with therapy for osteoporosis. *Arthritis Care Res* 2010;62:1440-1445.

Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adherence and occurrence of fractures after switching to once-monthly oral bisphosphonates. *Pharmacoepi Drug Saf* 2010;19:1233-1240.

Mazor KM, Velten S, Andrade SE, Yood RA. Older Women's Views about Prescription Osteoporosis Medication: A Cross-Sectional, Qualitative Study. *Drugs Aging* 2010;27:999-1008.

Solomon DH, Brookhart MA, Tsao P, Sundaresan D, Andrade SE, Mazor K, Yood R. Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. *Osteoporos Int* 2011;22:1737-1743.

Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Dublin S, Platt R. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiol Drug Saf* 2011;20:138-45.

Andrade SE, Moore Simas TA, Boudreau D, Raebel MA, Toh S, Syat B, Dashevsky I, Platt R. Validation of algorithms to ascertain clinical conditions and medical procedures used during pregnancy. *Pharmacoepidemiol Drug Saf* 2011;20:1168-1176.

Li D, Yang C, Andrade S, Tavares V. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and the risk of malformations in offspring: a retrospective cohort study. *BMJ* 2011;343:d5931.

Andrade SE, Lo JC, Roblin DR, Fouayzi H, Connor DF, Penfold RB, Chandra M, Reed G, Gurwitz JH. Antipsychotic medication use in children and risk of diabetes mellitus. *Pediatrics* 2011;128:1135-1141.

Saczynski JS, Andrade SE, Harrold LR, Tjia J, Cutrona SL, Dodd KS, Goldberg RJ, Gurwitz JH A systematic review of validated methods for identifying heart failure using administrative data. *Pharmacoepidemiol Drug Saf* (in press)

Andrade SE, Harrold LR, Tjia J, Cutrona SL, Saczynski JS, Dodd KS, Goldberg RJ, Gurwitz JH. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. *Pharmacoepidemiol Drug Saf* (in press)

Andrade SE, Davis RL, Cheetham TC, Cooper WO, Li D, Amini T, Beaton SJ, Dublin S, Hammad TA, Pawloski PA, Raebel MA, Smith DH, Staffa JA, Toh S, Dashevsky I, Haffenreffer K, Lane K, Platt P, Scott PE. Medication Exposure in Pregnancy Risk Evaluation Program. *Matern Child Health J* (in press)

Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA* 2011 (in press)

### **Abstracts**

Andrade SE, Walker AM. Determinants of adverse effects and therapeutic failure with antihyperlipidemic drug therapy. *J Clin Res Pharmacoepidemiol* 1991;5(2):131-132.

Andrade SE, Saperia GM, Gottlieb LK, Walker AM, Platt R. Effects of gender and age on the discontinuation rate of antihyperlipidemic drug therapy. *Pharmacoepidemiol Drug Saf* 1994;3(Supp.1):S20.

Andrade SE, Walker AM, Platt R, Hollenberg NK, Testa MA, Saperia GM, Gottlieb LK. Antihyperlipidemic drug discontinuations: Do rates reported in clinical trials predict rates in primary care settings? *Pharmacoepidemiol Drug Saf* 1994;3(Supp.1):S20.

Andrade SE, Platt R, Gottlieb LK, Saperia GM, Walker AM. Discontinuation of drug therapy: assessment by means of automated databases. *Pharmacoepidemiol Drug Saf* 1994;3(Supp.1):S21.

Martinez C, Andrade S, Weidman E. Mortality from short-term use of non-steroidal anti-inflammatory drugs and non-narcotic analgesics. *Pharmacoepidemiol Drug Saf* 1996;5(Suppl 1):S99.

Ward A, Willey C, Andrade S, Laforge R. Divergence from NIH guidelines for pharmacologic therapy and risk of adverse outcomes in asthmatic children: a historical cohort study. *Pharmacoepidemiol Drug Saf* 1998;7(Suppl 2):S138.

Ward A, Willey C, Andrade S, Laforge R. Medications and patient education provided to asthmatic children: a historical cohort study of the implementation of NIH recommendations. *Pharmacoepidemiol Drug Saf* 1998;7(Suppl 2):S149.

Harrold LR, Gurwitz JH, Field TS, Andrade SE, Fish LS, Jarry PD, Yood R. The diffusion of a novel therapy into general medical practice: the case of sildenafil. *Pharmacoepidemiol Drug Saf* 1999;8(Suppl 2):S91.

Andrade SE, Gurwitz JH, Fish LS, Cernieux J, Yood R. Evaluation of a comprehensive formulary switch in the managed care setting: the case of hormone replacement therapy. *Pharmacoepidemiol Drug Saf* 1999;8(Suppl 2):S91.

Andrade SE, Donahue JG, Chan KA, Watson DJ, Platt R. Hepatic transaminase testing frequency and patterns in patients on HMG-CoA reductase inhibitors. *Pharmacoepidemiol Drug Saf* 2000;9(Suppl

1):S29.

Goodman MJ, Gurwitz JH, Chan A, Andrade SE, DeFor TA, Platt R. Tramadol and the initiation of anticonvulsant therapy. *Pharmacoepidemiol Drug Saf* 2000;9(Suppl 1):S82.

Donahue JG, Chan KA, Andrade SE, Beck A, Boles M, Buist DS, Carey VJ, Chandler J, Chase GA, Ettinger B, Fishman P, Goodman MJ, Guess HA, Gurwitz JH, Lacroix AZ, Levin TR, Platt R. Alendronate, osteoporotic fracture, and gastroduodenal perforation, ulcer, or bleeding. *Pharmacoepidemiol Drug Saf* 2000;9(Suppl 1):S112.

Andrade SE, Gurwitz JH. Drug benefit plans under managed care: to what extent do elderly subscribers selecting less drug coverage put themselves at increased financial responsibility? *Pharmacoepidemiol Drug Saf* 2001;10(Suppl 1):S39.

Putnam KG, Chan KA, Fishman PA, Buist DS, Andrade SE, Beck A, Boles M, Goodman MJ, Gurwitz JH, Platt R. Chronic disease score as a predictor of subsequent hospitalization: a multi-HMO study. *Pharmacoepidemiol Drug Saf* 2001;10(Suppl 1):S139.

Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, Raebel MA, Smith DH, Platt R, Gurwitz JH. Treatment of osteoporosis among older women following an osteoporotic fracture. *Pharmacoepidemiol Drug Saf* 2002;11(Suppl 1):S52.

Andrade SE, Willey C, Cohen J, Gurwitz JH. Antidiabetic drug treatment patterns and glycemic control in a U.S. managed care population. *Pharmacoepidemiol Drug Saf* 2005;14(Suppl 1):S117.

Briesacher B, Andrade S, Kahler KH, Yood RA. Economic impact of the previous year's adherence with bisphosphonates. *Arthritis Rheum* 2006;54:S85-S86.

### ***Book Chapters***

Andrade SE, Gurwitz JH. Pharmacoepidemiology and the Elderly. In: *Drugs and the Older Person*, ed. Crome P., Ford G. London: Imperial College Press; 2000.

McPhillips H, Stille C, Smith D, Pearson J, Stull J, Hecht J, Andrade S, Miller M, Davis R. Methodological Challenges in Describing Medication Dosing Errors in Children. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. *Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology)*. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb.

Andrade SE, Chang JT. Cerivastatin and Rhabdomyolysis. In: *Pharmacoepidemiology and Therapeutic Risk Management*, ed. Hartzema AG., Tilson HH., Chan KA. Cincinnati, OH: Harvey Whitney Press; 2008.

Andrade SE, Raebel MA, Boudreau D, Davis RL, Haffenreffer K, Pawloski PA, Toh S, Platt R. Health Maintenance Organizations / Health Plans. In: Strom BL, ed. *Pharmacoepidemiology*. 5<sup>th</sup> Edition. Chichester, UK: John Wiley; (in press).